The aim of this clinical study is to assess the clinical efficacy Linear COVID-19 DNA vaccine, a candidate genetic vaccine against COVID-19 aiming to protect naїve minks from SARS-CoV-2 infection with the generation of measurable immune responses. Vaccination will consist of the injection of linear DNA amplicons (designed by Evvivax and manufactured by Applied DNA Science) codifying for a variant of the Spike protein of SARS-CoV-2 into the epaxial or tibialis muscle, followed by the electroporation carried out with Vet-ePorator™, or a hand-held gene-ePorator device manufactured by IGEA (Carpi, Modena, Italy) for Evvivax and based on Cliniporator® Technology. The Vet-Eporator electro-gene transfer technology is established and proven in many animal studies, while the hand-held gene-ePorator is being evaluated in the present study.